Polyinosinic-polycytidylic acid

Polyinosinic-polycytidylic acid (Poly(I:C)) is a synthetic analog of double-stranded RNA and an agonist of toll-like receptor 3 (TLR3) and retinoic acid inducible gene I (RIG-I)-like receptors (RIG-I and MDA5). Polyinosinic-polycytidylic acid can be used as a vaccine adjuvant to enhance innate and adaptive immune responses, and to alter the tumor microenvironment. Polyinosinic-polycytidylic acid can directly trigger cancer cells to undergo apoptosis[1][2].

[1]Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature. 2001;413(6857):732-738. |[2]Matsumoto M, Kikkawa S, Kohase M, Miyake K, Seya T. Establishment of a monoclonal antibody against human Toll-like receptor 3 that blocks double-stranded RNA-mediated signaling. Biochem Biophys Res Commun. 2002;293(5):1364-1369. |[3]Cheng Y, Xu F. Anticancer function of polyinosinic-polycytidylic acid [J]. Cancer biology & therapy, 2010, 10(12): 1219-1223.|[4]Deleidi M, Hallett P J, Koprich J B, et al. The Toll-like receptor-3 agonist polyinosinic: polycytidylic acid triggers nigrostriatal dopaminergic degeneration [J]. Journal of Neuroscience, 2010, 30(48): 16091-16101.|[5]Forte G, Rega A, Morello S, et al. Polyinosinic-polycytidylic acid limits tumor outgrowth in a mouse model of metastatic lung cancer [J]. The Journal of Immunology, 2012, 188(11): 5357-5364.|[6]Rezaee F, Meednu N, Emo J A, et al. Polyinosinic: polycytidylic acid induces protein kinase D–dependent disassembly of apical junctions and barrier dysfunction in airway epithelial cells [J]. Journal of Allergy and Clinical Immunology, 2011, 128(6): 1216-1224. e11.|[7]Wang P F, Fang H, Chen J, et al. Polyinosinic-polycytidylic acid has therapeutic effects against cerebral ischemia/reperfusion injury through the downregulation of TLR4 signaling via TLR3 [J]. The Journal of Immunology, 2014, 192(10): 4783-4794.Autophagy. 2024 May 18.|Biochem Biophys Res Commun. 2024 Feb 15, 149661.|bioRxiv. 2024 Dec 8:2024.12.07.627371.|bioRxiv. 2024 September 23.|Cancer Immunol Res. 2024 Jul 11.|Cancer Med. 2023 Jun 7.|Chem Biol Drug Des. 2023 Nov;102(5):1110-1120.|Chem Eng J. 2021 Aug 15;418:129392.|Clin Cosmet Investig Dermatol. 2024 May 14:17:1093-1105.|Clin Transl Med. 2024 Sep;14(9):e70027.|Curr Microbiol. 2024 Aug 6;81(9):296.|FASEB J. 2024 Mar 31.|Res Sq. 2024 Nov 14.|SSRN. 2023 Apr 29.|Vet Res. 2024 Sep 27;55(1):115.|Virol Sin. 2023 Aug 24;S1995-820X(23)00104-9.|Virol Sin. 2023 May 2;S1995-820X(23)00048-2.|Adv Funct Mater. 29 August 2022.|Liver Int. 2022 Oct 17.|Mol Ther Oncolytics. 25 August 2022.|Phytomedicine. 2021, 153495.|SSRN. 2021 Apr 26.